Cancer immunotherapy

Catamaran Bio Launches with $42 Million Financing to Develop Off‑the‑Shelf CAR-NK Cell Therapies to Treat Solid Tumors

Retrieved on: 
Monday, November 23, 2020

Catamaran Bio, Inc. , a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, today announced that the company has launched with $42 million in financing.

Key Points: 
  • Catamaran Bio, Inc. , a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, today announced that the company has launched with $42 million in financing.
  • To date, the success of autologous CAR T-cell therapies in hematological malignancies has opened the door to the breakthrough potential of cell therapies for cancer, and Catamaran is now well positioned to improve upon this groundwork by developing off-the-shelf CAR-NK cell therapies capable of reaching solid tumors.
  • Catamaran is focused on expanding the frontier of cell therapies to treat solid tumors and provide transformative benefit to cancer patients.
  • Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors.

Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19

Retrieved on: 
Sunday, November 22, 2020

The safety and effectiveness of this investigational therapy for use in the treatment of COVID-19 continues to be evaluated.

Key Points: 
  • The safety and effectiveness of this investigational therapy for use in the treatment of COVID-19 continues to be evaluated.
  • A benefit of casirivimab and imdevimab treatment has not been shown in patients hospitalized due to COVID-19.
  • Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system," said FDA Commissioner Stephen M. Hahn, M.D.
  • Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens such as viruses.

Ziopharm Releases Investor Presentation Highlighting Execution of Strategy and Substantial Board Refreshment to Enhance Shareholder Value

Retrieved on: 
Friday, November 20, 2020

We also reported key new executive hires and strong third quarter results that demonstrate our continued execution and clinical progress to advance our mission to treat cancer patients with potentially transformational therapies.

Key Points: 
  • We also reported key new executive hires and strong third quarter results that demonstrate our continued execution and clinical progress to advance our mission to treat cancer patients with potentially transformational therapies.
  • Our recent investor presentation outlines these positive changes and strategic initiatives as well as an array of other facts and upcoming catalysts that we believe help advance our goal of delivering long-term shareholder value.
  • The investor presentation and other important materials related to the WaterMill consent solicitation can be found at www.ZiopharmForward.com .
  • With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor.

Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day

Retrieved on: 
Friday, November 20, 2020

The link to register is HERE and further background information on Adaptimmune and the event can be found HERE .

Key Points: 
  • The link to register is HERE and further background information on Adaptimmune and the event can be found HERE .
  • After the event, a copy of the presentation materials and webcast links will be posted on the Events and Presentations page under the Investors section of the Adaptimmune website.
  • We will lay out the strategy confirming our leadership position as a company designing and delivering cell therapies for people with cancer, said Adrian Rawcliffe, Adaptimmunes Chief Executive Officer.
  • Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer.

IMFINZI® (durvalumab) Approved In The US For Less-Frequent, Fixed-Dose Use

Retrieved on: 
Friday, November 20, 2020

IMFINZI is also approved for previously treated patients with advanced bladder cancer in the US and several other countries.

Key Points: 
  • IMFINZI is also approved for previously treated patients with advanced bladder cancer in the US and several other countries.
  • Immune-mediated colitis occurred in 1.6% (31/1889) of patients receiving IMFINZI, including Grade 4 (0.1%) and Grade 3 (0.3%) adverse reactions.
  • Immune-mediated hepatitis occurred in 1.0% (19/1889) of patients receiving IMFINZI, including fatal (
  • Immune-mediated adrenal insufficiency occurred in 0.4% (7/1889) of patients receiving IMFINZI, including Grade 3 (

CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December

Retrieved on: 
Friday, November 20, 2020

CT053 is an investigational anti-BCMA (B cell maturation antigen) autologous chimeric antigen receptor (CAR) T-cell product for the treatment of adult patients with relapsed and/or refractory multiple myeloma.

Key Points: 
  • CT053 is an investigational anti-BCMA (B cell maturation antigen) autologous chimeric antigen receptor (CAR) T-cell product for the treatment of adult patients with relapsed and/or refractory multiple myeloma.
  • These are open-label, multicenter studies evaluating the safety and efficacy of CT053 in adult patients with relapsed and/or refractory multiple myeloma.
  • CARsgen Therapeutics is a clinical-stage immuno-oncology company committed to the development of first-in-class and best-in-class CAR T-cell and antibody therapeutics.
  • CARsgen also has ongoing clinical CAR T-cell programs with a humanized CAR-CD19 for leukemia and lymphoma.

Immunomic Therapeutics and CoImmune Therapeutics Enter into Partnership to Manufacture ITI-1020, a Novel Experimental Cell Therapy for Glioblastoma

Retrieved on: 
Thursday, November 19, 2020

The partnership highlights the oncology pipeline of ITI and CoImmunes expertise and technology in the development and manufacture of cell-based therapeutics.

Key Points: 
  • The partnership highlights the oncology pipeline of ITI and CoImmunes expertise and technology in the development and manufacture of cell-based therapeutics.
  • We are excited to work with CoImmune, an emerging leader in the development and manufacture of cell-based immunotherapies, said Dr. Tim Coleman, Senior Vice President of Operations at Immunomic Therapeutics.
  • We look forward to collaborating with CoImmune and harnessing their expertise in cell therapies to bring our innovative products to patients in need.
  • Our industry is experiencing an increase in the emergence of cell-based therapeutics based on encouraging clinical results to date.

VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM

Retrieved on: 
Thursday, November 19, 2020

VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI") a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced Phase 2a (Part B) data from its ongoing Phase 1/2a study of VBI-1901, the companys cancer vaccine immunotherapeutic candidate designed to target cytomegalovirus (CMV) as a foreign viral antigen in recurrent glioblastoma (GBM).

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI") a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced Phase 2a (Part B) data from its ongoing Phase 1/2a study of VBI-1901, the companys cancer vaccine immunotherapeutic candidate designed to target cytomegalovirus (CMV) as a foreign viral antigen in recurrent glioblastoma (GBM).
  • Few treatment options are available to recurrent glioblastoma patients, and the tumor response data seen to-date in this ongoing study are encouraging.
  • A copy of the e-poster is available on the Events/Presentations page in the Investors section of the VBI Vaccines website.
  • This phase enrolled 18 recurrent GBM patients across three dose cohorts of VBI-1901: 0.4 g, 2.0 g, and 10.0 g.
    Enrollment completed in December 2018.

Immutep Announces Expansion of TACTI-002 Collaboration Trial

Retrieved on: 
Wednesday, November 18, 2020

The expansion extends Immuteps existing clinical trial collaboration and supply agreement with MSD (announced on 12 March 2018).

Key Points: 
  • The expansion extends Immuteps existing clinical trial collaboration and supply agreement with MSD (announced on 12 March 2018).
  • In addition, efti plus pembrolizumab continues to be safe and well tolerated with no new safety signals reported so far.
  • Immutep CEO, Marc Voigt said: We are excited to expand our collaboration trial with MSD, one of the worlds leading immuno-oncology companies.
  • Separately, Immutep has commenced planning for a new Phase II, randomised, controlled clinical study in approximately 160 1st line HNSCC patients.

World Cancer Immunotherapy Market Analysis & Forecasts 2020-2025 with CAR T Therapy Company Case Studies

Retrieved on: 
Wednesday, November 18, 2020

DUBLIN, Nov. 18, 2020 /PRNewswire/ -- The "Global Cancer Immunotherapy Market Analysis & Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 18, 2020 /PRNewswire/ -- The "Global Cancer Immunotherapy Market Analysis & Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • An overview of cancer immunotherapy that includes: monoclonal antibodies, ADC's, cancer vaccines and non-specific cancer immunotherapies and CAR T therapies.
  • Focus on current trends in cancer immunotherapies that include: anti-PD-1 and anti-PDL1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines.
  • Overall global cancer therapeutics market, leading market players and the best selling cancer drugs.